Drug Profile
Research programme: anti-cancer therapeutics - Allgenesis Biotherapeutics
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator Allgenesis Biotherapeutics
- Class Antineoplastics; Disintegrins
- Mechanism of Action Integrin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Cancer in Taiwan
- 17 Mar 2017 Early research in Cancer in Taiwan (unspecified route) (Allgenesis Biotherapeutics pipeline, March 2017)